Clinical Trials Logo

Clinical Trial Summary

Up to 12 subjects will be enrolled. Enrolled subjects will receive one or two Ultherapy treatments on the cheeks, depending on their assigned study group. Follow-up visits will occur 14, 30 and 90 days post-treatment. Study images will be obtained pre-treatment, 30-60 min post-treatment, and at each follow-up visit.


Clinical Trial Description

This study is a prospective, randomized, single-center clinical trial. The study will be conducted in two Phases. In Phase I, subjects will be assigned to one of two treatment groups. One study group will receive one dual depth Ultherapy treatment to a region on the cheeks, and one study group will receive two dual depth Ultherapy treatments to a region on the cheeks 14 days apart. Average pain scores will be obtained using a Numeric Rating Scale following each region of treatment and for each depth of treatment. In Phase II, based on observations of last follow-up visit in Phase I (at 90 days after treatment), subjects will be given the option to receive treatment of the affected area(s) for the protocol specified region, treated at the treatment depth showing the most efficacy in Phase I. Efficacy will be determined by improvement in Erythematotelangiectatic Rosacea in the treatment area versus control (an untreated area) as determined by primary investigator assessment at the last follow-up visit in Phase I. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01756027
Study type Interventional
Source Merz Pharmaceuticals, LLC
Contact
Status Completed
Phase N/A
Start date November 2012
Completion date October 2013

See also
  Status Clinical Trial Phase
Terminated NCT03708263 - Evaluation of the New Laser PHOTOLASE PLV-585nm for the Treatment of Rosacea N/A
Completed NCT02268474 - Excel V 532 nm KTP Laser for Treatment of Erythematotelangiectatic Rosacea & Papulopustular Rosacea N/A
Completed NCT00989014 - Dose-Finding Study of CD07805/47 Topical Gel in Subjects With Erythematotelangiectatic Rosacea Phase 2
Completed NCT06331533 - Intradermal BoNT-A Treatment in Erythematotelangiectatic Rosacea Phase 4
Completed NCT02144181 - Ultherapy® for the Treatment of Erythematotelangiectatic Rosacea N/A
Recruiting NCT05360251 - Pulsed Dye Laser and Intense Pulsed Light Configured With Different Wavelength Bands in Improving Erythematotelangiectatic Rosacea N/A
Completed NCT01045551 - Open Label Pilot Study of Apremilast in Treatment of Rosacea Phase 2
Completed NCT00945373 - Combination Therapy for the Treatment of Rosacea Phase 1
Completed NCT04153188 - Pulsed Dye Laser Treatment and Oxymetazoline Hydrochloride (HCL) 1% Cream for Erythematotelangiectatic Rosacea Phase 4
Completed NCT02393937 - A Therapeutic Equivalence Study of Two Metronidazole Gel 1% Topical Treatments of Rosacea Phase 3
Completed NCT02052999 - Study to Evaluate the Efficacy and Safety of PAC-14028 Cream in Rosacea Patients Phase 2